 |
市場調查報告書
商品編碼
1789537
原發性膽汁性膽管炎治療市場依治療類型、通路及地區分類Primary Biliary Cholangitis Treatment Market By Treatment Type, By Distribution Channel, By Region |
||||||
價格
簡介目錄
原發性膽汁性膽管炎治療市場規模預計在 2025 年為 7.694 億美元，預計到 2032 年將達到 13.885 億美元，2025 年至 2032 年的複合年成長率為 8.8%。
| 報告範圍 | 報告詳細資訊 | ||
|---|---|---|---|
| 基準年 | 2024 | 2025年的市場規模 | 7.694億美元 |
| 效能數據 | 2020-2024 | 預測期 | 2025-2032 |
| 預測期：2025-2032年 | 8.80% | 2032年預測 | 13.885億美元 |
原發性膽汁性膽管炎 (PBC) 是一種慢性自體免疫肝病，會影響肝臟中的小膽管。隨著疾病的進展，這些膽管（稱為小管）會形成疤痕而受損，導致膽汁無法在肝臟內自由流動，久而久之會導致肝損傷。 PBC 的主要症狀包括疲倦、搔癢和黃疸。如果不及時原發性，PBC 最終會導致肝硬化和肝功能衰竭。 PBC 治療市場由與該疾病的發病機制和進展有關的各種途徑的藥物組成。雖然熊去氧膽酸 (UDCA) 仍然是一線治療藥物，但許多患者對該藥物反應不足或不耐受。二線治療藥物（如奧貝膽酸和纖維酸衍生物）正在興起，以滿足尚未滿足的需求。
市場動態
原發性膽汁性膽管炎治療市場主要受全球 PBC 盛行率上升的驅動。據多方估計，全球 PBC 盛行率為每百萬人 40 至 400 例。市場也受到新型二線治療方法的推出的推動，這些藥物比傳統治療方法具有更高的療效和更好的耐受性。然而，新藥成本高和市場對 PBC 認知度低等因素阻礙了它們的發展。具有新作用機制的在研藥物的出現為該市場的參與企業帶來了機會。高效安全的治療方法如果獲得監管機構的核准，可以滿足難治性患者的需求。
本次調查的主要特點
- 本報告對全球原發性膽汁性膽管炎治療市場進行了詳細分析，並以 2024 年為基準年，介紹了預測期 2025-2032 的市場規模（美國、緬甸）和複合年成長率。
- 它還強調了各個領域的潛在收益成長機會，並說明了針對該市場的引人注目的投資提案。
- 它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景以及主要企業採用的競爭策略的主要考察。
- 全球原發性膽汁性膽管炎治療市場的主要企業已根據以下參數進行了分析，例如公司亮點、產品系列、關鍵亮點、績效和策略。
- 本研究涉及的關鍵公司包括 Intercept Pharmaceuticals, Inc.、Highlight Therapeutics, SL、GSK plc.、Bristol-Myers Squibb and Company、Enanta Pharmaceuticals、NW BIoTherapeutics、Merck & Cor.、Ipsen Pharma、Johnson & Johnson、GENFIT、Ironr. Pharmaceutical Co., Ltd.
- 本報告的見解將使負責人和企業經營團隊能夠就未來的產品發布、規模擴大、市場擴張和行銷策略做出明智的決策。
- 全球原發性膽汁性膽管炎治療市場報告涉及該行業的各個相關人員，例如投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
- 相關人員將透過全球原發性膽汁性膽管炎治療市場分析中使用的各種策略矩陣更輕鬆地做出決策。
目錄
第1章：調查目標和先決條件
- 調查目的
- 先決條件
- 簡稱
第2章 市場展望
- 報告描述
- 市場定義和範圍
- 執行摘要
- 一致的機會圖（COM）
第3章：市場動態、法規與趨勢分析
- 市場動態
- 原發性膽汁性膽管炎盛行率不斷上升
- 擴大新藥的採用
- 擴大聯合治療的應用
- 影響分析
- 監管情景
- 產品發布/核准
- PEST分析
- 波特分析
- 併購場景
第4章原發性膽汁性膽管炎治療市場（依治療類型），2020 年至 2032 年
- 介紹
- 熊去氧膽酸（UDCA）
- 奧貝膽酸（奧卡利夫）
- 其他（貝特類藥物（Tricol）等）
第5章原發性膽汁性膽管炎治療市場（依通路分類）2020-2032 年
- 介紹
- 醫院藥房
- 零售藥局
- 網路藥局
第6章原發性膽汁性膽管炎治療市場（按地區），2020-2032 年
- 介紹
- 北美洲
- 美國
- 加拿大
- 歐洲
- 德國
- 英國
- 西班牙
- 法國
- 義大利
- 俄羅斯
- 其他歐洲國家
- 亞太地區
- 印度
- 中國
- 日本
- 澳洲
- 東南亞國協
- 韓國
- 其他亞太地區
- 拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲
- 中東
- 海灣合作理事會國家
- 以色列
- 其他中東地區
- 非洲
- 北非
- 中部非洲
- 南非
第7章 競爭態勢
- Intercept Pharmaceuticals, Inc.
- Highlight Therapeutics, SL
- GSK plc.
- Bristol-Myers Squibb and Company
- Enanta Pharmaceuticals
- NW BIoTherapeutics
- Merck & Co Inc.
- Ipsen Pharma
- Johnson & Johnson
- GENFIT
- Ironwood Pharmaceuticals, Inc.
- Novartis AG
- COUR Pharmaceuticals
- Kaken Pharmaceutical Co., Ltd.
第 8 章 章節
- 調查方法
- 關於出版商
簡介目錄
Product Code: CMI2555
Primary Biliary Cholangitis Treatment Market is estimated to be valued at USD 769.4 Mn in 2025 and is expected to reach USD 1,388.5 Mn by 2032, growing at a compound annual growth rate (CAGR) of 8.8% from 2025 to 2032.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 769.4 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 8.80% | 2032 Value Projection: | USD 1,388.5 Mn |
Primary Biliary Cholangitis (PBC) is a chronic autoimmune liver disease that affects the small bile ducts in the liver. As the disease progresses, it causes scarring and injury to these bile ducts, known as bile ductules, which stops bile from flowing freely within the liver and damaging it over time. Some key symptoms of PBC include fatigue, itching, and jaundice. If left untreated, PBC can eventually result in cirrhosis or liver failure. The primary biliary cholangitis treatment market consists of drugs that target various pathways involved in the pathogenesis and progression of the disease. Ursodeoxycholic acid (UDCA) remains the first-line treatment but many patients do not adequately respond or are intolerant to it. Second-line treatments such as obeticholic acid and fibric acid derivatives are emerging to address the unmet needs.
Market Dynamics
The primary biliary cholangitis treatment market is primarily driven by the rising prevalence of PBC globally. According to various estimates, the global prevalence of PBC ranges between 40 and 400 cases per million. The market is also propelled by the launch of novel second-line treatment options with higher efficacy and better tolerability profiles than conventional therapies. However, the market growth can be restrained by the high costs of newer drugs and lack of awareness about PBC in developing regions. Emergence of pipeline drugs with novel mechanisms of action represents an opportunity for players in this market. Regulatory approval of efficient and safe therapies can help address the needs of refractory patients.
Key Features of the Study
- This report provides an in-depth analysis of the global primary biliary cholangitis treatment market, and provides market size (US Mn) and compound annual growth rate (CAGR %) for the forecast period 2025-2032, considering 2024 as the base year.
- It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global primary biliary cholangitis treatment market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
- The key companies covered as a part of this study include Intercept Pharmaceuticals, Inc., Highlight Therapeutics, S.L., GSK plc., Bristol-Myers Squibb and Company, Enanta Pharmaceuticals, NW Biotherapeutics, Merck & Co Inc., Ipsen Pharma, Johnson & Johnson, GENFIT, Ironwood Pharmaceuticals, Inc., Novartis AG, COUR Pharmaceuticals, and Kaken Pharmaceutical Co., Ltd.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global primary biliary cholangitis treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global primary biliary cholangitis treatment market.
Market Segmentation
- By Treatment Type
- Ursodeoxycholic Acid (UDCA)
- Obeticholic Acid (Ocaliva)
- Others (Fibrates (Tricor), etc.)
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Top Companies in the Primary Biliary Cholangitis Treatment Market
- Intercept Pharmaceuticals, Inc.
- Highlight Therapeutics, S.L.
- GSK plc.
- Bristol-Myers Squibb and Company
- Enanta Pharmaceuticals
- NW Biotherapeutics
- Merck & Co Inc.
- Ipsen Pharma
- Johnson & Johnson
- GENFIT
- Ironwood Pharmaceuticals, Inc.
- Novartis AG
- COUR Pharmaceuticals
- Kaken Pharmaceutical Co., Ltd.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Primary Billiary Cholangitis Treatment, By Treatment Type
- Market Primary Billiary Cholangitis Treatment, By Distribution Channel
- Market Primary Billiary Cholangitis Treatment, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Increasing Prevalence of Primary Biliary Cholangitis
- Growing Adoption of Novel Drugs
- Increasing adoption of Combination Therapy
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
4. Primary Biliary Cholangitis Treatment Market, By Treatment Type, 2020-2032, (USD Mn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Ursodeoxycholic Acid (UDCA)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Obeticholic Acid (Ocaliva)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Others (Fibrates (Tricor), etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
5. Primary Biliary Cholangitis Treatment Market, By Distribution Channel, 2020-2032, (USD Mn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
6. Primary Biliary Cholangitis Treatment Market, By Region, 2020-2032, (USD Mn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Mn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Mn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Mn)
- India
- China
- Japan
- Australia
- ASEAN
- South Korea
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Mn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020 - 2032, (USD Mn)
- North Africa
- Central Africa
- South Africa
7. Competitive Landscape
- Intercept Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Highlight Therapeutics, S.L.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- GSK plc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bristol-Myers Squibb and Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Enanta Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- NW Biotherapeutics
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck & Co Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Ipsen Pharma
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- GENFIT
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Ironwood Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- COUR Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Kaken Pharmaceutical Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Analyst Views
8. Section
- Research Methodology
- About us
02-2729-4219
+886-2-2729-4219
原發性硬化性膽管炎市場按藥物類別、給藥途徑、分銷管道和地區分類
原發性膽汁性膽管炎治療市場 - 按藥物（熊去氧膽酸、奧貝膽酸）、用途（人類、獸醫）、配銷通路（醫院藥房、藥房和零售藥房、在線藥房） - 全球預測（ 2024 - 2032）